HC Wainwright & Co. maintains Actuate Therapeutics at Buy, lowers price target to $10 from $15
HC Wainwright & Co. kept its Buy rating on Actuate Therapeutics but reduced its price target to $10 from $15, a 33.3% cut. The new target suggests a 3405.1% upside from the Nov 13 close of $0.29.
How this was made

The 30-second read
Why it matters
The downgrade may prompt short‑term selling but does not reflect a fundamental change in the company's operations.
Market read
A modest analyst downgrade with limited market impact; primarily relevant to traders holding or watching ACTU.
What to watch
No new corporate events; the move is purely analyst opinion.
Background
Actuate Therapeutics is a micro‑cap biotech with recent volatility; analyst coverage is sparse.
Ticker impact
HC Wainwright lowered its price target for Actuate Therapeutics to $10 from $15, indicating a bearish analyst view.
likely pressure as the market prices in the lower target
The price‑target cut reflects reduced expectations and may trigger sell‑offs.
Market effects
Minor impact on the biotech sector; similar small‑cap stocks may see slight sentiment drag.
Limited to U.S. micro‑cap biotech investors.
Low
Counterpoint
Some investors may view the lower target as a buying opportunity if they believe the stock is undervalued.
Key entities
- analystHC Wainwright & Co.
Equity research firm that issued the price‑target cut.
- companyActuate Therapeutics
Biotech firm whose stock is affected by the analyst downgrade.

